Ilan Katz is a member of Dentons' Corporate and Business Transactions and Venture Technology practices.
His practice encompasses a number of major transactional areas, including mergers and acquisitions, venture capital transactions, joint ventures and strategic alliances, structured and project finance, general contract negotiation, and general corporate advice.
Ilan has extensive experience representing a wide variety of public and private companies in numerous corporate transactions.
Experience:
Big Cypress Acquisition Corp: Advised Big Cypress Acquisition Corp. on its initial public offering on the Nasdaq. This special purpose acquisition company IPO, which includes the full exercise of the underwriters’ over-allotment option, resulted in total gross proceeds of $115 million.
Immunic: Represented this clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases in its April 2019 reverse merger transaction that resulted in its listing on Nasdaq.
Arcturus Therapeutics: Represented this preclinical drug delivery and RNA medicines company in connection with its collaboration and equity investment transaction with Ultragenyx.
Biscayne Neurotherapeutics: Represented this privately-held company developing a novel treatment for epilepsy in connection with its sale to Supernus Pharmaceuticals.
PharmAthene: Represented this biodefense company in connection with its business combination with Altimmune, a clinical stage biopharmaceutical company.
How do I contact Ilan Katz?
Has Ilan Katz been buying or selling shares of Big Cypress Acquisition?
Ilan Katz has not been actively trading shares of Big Cypress Acquisition during the past quarter. Most recently, on Wednesday, October 13th, Ilan Katz bought 500 shares of Big Cypress Acquisition stock. The stock was acquired at an average cost of $10.11 per share, with a total value of $5,055.00. Learn More on Ilan Katz's trading history.
Who are Big Cypress Acquisition's active insiders?
